Novartis (NVS) announced new Phase II data showing AIN457, or secukinumab, may significantly improve moderate-to-severe plaque psoriasis on the hands, feet and nails when used every week for the first month of treatment, compared to placebo. Additional analysis on patients with moderate-to-severe plaque psoriasis also showed that AIN457 may successfully improve quality of life by Week 12 in the study. The results will be presented on Sept. 27 at the European Academy of Dermatology and Venereology 21st Congress, in Prague, Czech Republic.
The study safety analysis of the data showed a comparable safety profile between treatment and placebo, with the most common adverse events observed being infections.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.